Product Information

TIAGABINE HCL 4 MG TABLET is a generic product labeled by Novadoz Pharmaceuticals LLC, priced at $3.6306 per EA under NDC 72205008530. Its NADAC has been published 234 times since Jun 1, 2022.

FDA first approved this application on Nov 16, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TIAGABINE HCL 4 MG TABLET

Tiagabine Hydrochloride
$3.6306per EA

Strength

4 mg/1

NDC

72205008530

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

TIAGABINE HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA214816

FDA Approved

11/16/2021

TE Code

AB

On Market Since

11/23/2021

Pharmacological Classes

Anti-epileptic Agent
Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for TIAGABINE HCL 4 MG TABLET has been published 234 times since Jun 1, 2022, and over the history we have for it it has risen 3.1%. The table below summarizes its recorded NADAC range and movement.

Current price$3.6306 per EA
All-time high$3.6306 (Nov 18, 2026)
All-time low$1.6211 (Nov 19, 2025)
52-week high$3.6306
52-week low$1.6211
Median price$2.3538
Average price$2.4861
Largest weekly change+43.0% (Mar 20, 2024)
Weeks tracked234
Tracking sinceJun 1, 2022

Price History

1W

+18.5%

1M

+43.8%

3M

+59.7%

6M

+80.4%

1Y

+124.0%

3Y

+13.9%

5Y

N/A

All

+3.1%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 16% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 16%

1 alternative • Same active ingredient

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TIAGABINE HCL 4 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for TIAGABINE HCL 4 MG TABLET, manufactured by Novadoz Pharmaceuticals LLC, is $3.6306 per EA (NDC 72205008530), effective Nov 18, 2026.

How has the price of TIAGABINE HCL 4 MG TABLET changed over time?

Over the history we have for it, the NADAC for TIAGABINE HCL 4 MG TABLET has risen 3.1%. It has been tracked across 234 weekly CMS publications since Jun 1, 2022.

What are the highest and lowest recorded NADAC prices for TIAGABINE HCL 4 MG TABLET?

Since Jun 1, 2022, the NADAC for TIAGABINE HCL 4 MG TABLET has ranged from a low of $1.6211 (Nov 19, 2025) to a high of $3.6306 (Nov 18, 2026), with a median of $2.3538 per EA.

Are there cheaper alternatives to TIAGABINE HCL 4 MG TABLET?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TIAGABINE HCL 4 MG TABLET, is $3.0645 per EA — about 16% below TIAGABINE HCL 4 MG TABLET.

Who manufactures TIAGABINE HCL 4 MG TABLET?

TIAGABINE HCL 4 MG TABLET (NDC 72205008530) is labeled by Novadoz Pharmaceuticals LLC, and CMS classifies it as a generic product.